TABLE OF CONTENTS
1 INTRODUCTION 61
1.1 OBJECTIVES OF THE STUDY 61
1.2 MARKET DEFINITION 61
1.3 OVERVIEW OF THE GLOBAL LIQUID BIOPSY MARKET 61
1.4 LIMITATIONS 63
1.5 MARKETS COVERED 63
2 MARKET SEGMENTATION 67
2.1 MARKETS COVERED 67
2.2 GEOGRAPHICAL SCOPE 68
2.3 YEARS CONSIDERED FOR THE STUDY 69
2.4 CURRENCY AND PRICING 69
2.5 DBMR TRIPOD DATA VALIDATION MODEL 70
2.6 MULTIVARIATE MODELLING 73
2.7 PRODUCT TYPE LIFELINE CURVE 73
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 74
2.9 DBMR MARKET POSITION GRID 75
2.10 MARKET TESTING TYPE COVERAGE GRID 76
2.11 VENDOR SHARE ANALYSIS 77
2.12 SECONDARY SOURCES 78
2.13 ASSUMPTIONS 78
3 EXECUTIVE SUMMARY 79
4 PREMIUM INSIGHTS 82
4.1 PESTEL ANALYSIS 85
4.2 PORTERS FIVE FORCES 86
5 INDUSTRY INSIGHTS: 87
6 GLOBAL LIQUID BIOPSY MARKET, REGULATION 88
7 MARKET OVERVIEW 90
7.1 DRIVERS 92
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE 92
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY 93
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS 94
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS 95
7.2 RESTRAINTS 96
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS 96
7.2.2 LACK OF STANDARDIZED GUIDELINES 97
7.3 OPPORTUNITIES 98
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING 98
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY 99
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES 99
7.4 CHALLENGES 100
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY 100
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES 101
8 GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT 102
8.1 OVERVIEW 103
8.2 CONSUMABLES & ACCESSORIES 106
8.2.1 TEST KITS 107
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT 107
8.2.1.2 DNA ISOLATION KIT 107
8.2.1.3 OTHERS 107
8.2.2 COLLECTION TUBES 107
8.2.2.1 50 PIECES 108
8.2.2.2 100 PIECES 108
8.2.3 ASSAYS 108
8.2.3.1 FLEXIBLE REAGENTS 108
8.2.3.2 SCALABLE REAGENTS 108
8.2.3.3 OTHERS 108
8.2.4 CONTROL KIT 108
8.2.5 OTHERS 108
8.3 INSTRUMENTS 108
8.3.1 ANALYZERS 109
8.3.2 SYSTEMS 109
8.3.3 OTHERS 110
8.4 SERVICES & SOFTWARE 110
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE 111
8.4.2 DPCR ANALYSIS SOFTWARE 111
8.4.3 CASTPCR ANALYSIS SOFTWARE 111
8.4.4 OTHERS 111
9 GLOBAL LIQUID BIOPSY MARKET, BY BIOMAKER TYPE 112
9.1 OVERVIEW 113
9.2 CIRCULATING TUMOR CELLS (CTCS) 116
9.3 CIRCULATING CELL-FREE DNA (CFDNA) 117
9.4 CELL-FREE RNA 118
9.5 EXOSOMES 119
9.6 EXTRACELLULAR VESICLES 120
9.7 OTHERS 121
10 GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE TYPE 122
10.1 OVERVIEW 123
10.2 BLOOD SAMPLE-BASED 126
10.3 URINE SAMPLE-BASED 127
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED 128
10.5 OTHERS 129
11 GLOBAL LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE 130
11.1 OVERVIEW 131
11.2 MOLECULAR 134
11.2.1 NGS 135
11.2.2 PCR 135
11.2.3 MICROARRAY 135
11.2.4 PROTEOMICS 135
11.2.5 OTHERS 135
11.3 PROTEOMIC 135
11.3.1 NGS 136
11.3.2 PCR 136
11.3.3 MICROARRAY 136
11.3.4 PROTEOMICS 136
11.3.5 OTHERS 136
11.4 HISTOLOGY/IMAGING 137
12 GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION TYPE 138
12.1 OVERVIEW 139
12.2 CANCER APPLICATIONS 142
12.2.1 LUNG 143
12.2.2 BREAST 143
12.2.2.1 EARLY BREAST CANCER 143
12.2.2.2 ADVANCED BREAST CANCER 143
12.2.3 COLORECTAL 143
12.2.4 PROSTRATE 144
12.2.5 LIVER 144
12.2.6 OTHERS 144
12.3 NON-CANCER APPLICATIONS 144
12.3.1 PRENATAL DIAGNOSIS 145
12.3.2 PERSONALIZED IMMUNOTHERAPY 145
12.3.3 OTHERS 145
13 GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 146
13.1 OVERVIEW 147
13.2 ROUTINE SCREENING 150
13.3 THERAPY SELECTION 151
13.4 TREATMENT MONITORING 151
13.4.1 EARLY-STAGE DISEASE 152
13.4.2 LATE-STAGE/METASTATIC DISEASE 152
13.5 RECURRENCE MONITORING 153
13.6 PATIENT WORK-UP 153
13.7 OTHERS 154
14 GLOBAL LIQUID BIOPSY MARKET, BY TECHNOLOGY 155
14.1 OVERVIEW 156
14.2 MULTI-GENE-PARALLEL ANALYSIS 159
14.3 SINGLE GENE ANALYSIS 160
15 GLOBAL LIQUID BIOPSY MARKET, BY END USER 161
15.1 OVERVIEW 162
15.2 HOSPITALS 165
15.3 REFERENCE LABORATORIES 165
15.4 DIAGNOSTIC CENTERS 166
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES 166
15.6 OTHERS 168
16 GLOBAL LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL 169
16.1 OVERVIEW 170
16.2 DIRECT TENDER 173
16.3 THIRD PARTY DISTRIBUTOR 173
16.4 OTHERS 174
17 GLOBAL LIQUID BIOPSY MARKET, BY REGION 175
17.1 OVERVIEW 176
17.2 NORTH AMERICA 182
17.2.1 U.S. 196
17.2.2 CANADA 205
17.2.3 MEXICO 214
17.3 EUROPE 223
17.3.1 GERMANY 237
17.3.2 FRANCE 246
17.3.3 U.K. 255
17.3.4 ITALY 264
17.3.5 SPAIN 272
17.3.6 RUSSIA 280
17.3.7 TURKEY 288
17.3.8 BELGIUM 296
17.3.9 NETHERLANDS 304
17.3.10 SWITZERLAND 312
17.3.11 REST OF EUROPE 320
17.4 ASIA-PACIFIC 321
17.4.1 JAPAN 334
17.4.2 CHINA 342
17.4.3 SOUTH KOREA 351
17.4.4 INDIA 360
17.4.5 AUSTRALIA 367
17.4.6 SINGAPORE 376
17.4.7 THAILAND 384
17.4.8 MALAYSIA 392
17.4.9 INDONESIA 400
17.4.10 PHILIPPINES 407
17.4.11 REST OF ASIA-PACIFIC 417
17.5 SOUTH AMERICA 418
17.5.1 BRAZIL 430
17.5.2 ARGENTINA 437
17.5.3 REST OF SOUTH AMERICA 444
17.6 MIDDLE EAST AND AFRICA 445
17.6.1 SOUTH AFRICA 457
17.6.2 SAUDI ARABIA 464
17.6.3 U.A.E. 471
17.6.4 EGYPT 478
17.6.5 ISRAEL 485
17.6.6 REST OF MIDDLE EAST AND AFRICA 492
18 GLOBAL LIQUID BIOPSY MARKET, COMPANY LANDSCAPE 493
18.1 COMPANY SHARE ANALYSIS: GLOBAL 493
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 494
18.3 COMPANY SHARE ANALYSIS: EUROPE 495
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 496
19 COMPANY PROFILE 497
19.1 F. HOFFMANN-LA ROCHE LTD. 497
19.1.1 COMPANY SNAPSHOT 497
19.1.2 REVENUE ANALYSIS 497
19.1.3 COMPANY SHARE ANALYSIS 498
19.1.4 PRODUCT PORTFOLIO 498
19.1.5 RECENT DEVELOPMENTS 498
19.2 GUARDANT HEALTH 499
19.2.1 COMPANY SNAPSHOT 499
19.2.2 REVENUE ANALYSIS 499
19.2.3 COMPANY SHARE ANALYSIS 500
19.2.4 PRODUCT PORTFOLIO 500
19.2.5 RECENT DEVELOPMENTS 500
19.3 THERMO FISHER SCIENTIFIC INC. 501
19.3.1 COMPANY SNAPSHOT 501
19.3.2 REVENUE ANALYSIS 501
19.3.3 COMPANY SHARE ANALYSIS 502
19.3.4 SWOT ANALYSIS 502
19.3.5 PRODUCT PORTFOLIO 503
19.3.6 RECENT DEVELOPMENTS 504
19.4 EXACT SCIENCE CORPORATION 505
19.4.1 COMPANY SNAPSHOT 505
19.4.2 REVENUE ANALYSIS 505
19.4.3 COMPANY SHARE ANALYSIS 506
19.4.4 PRODUCT PORTFOLIO 506
19.4.5 RECENT DEVELOPMENTS 506
19.5 QIAGEN 507
19.5.1 COMPANY SNAPSHOT 507
19.5.2 REVENUE ANALYSIS 507
19.5.3 COMPANY SHARE ANALYSIS 508
19.5.4 PRODUCT PORTFOLIO 508
19.5.5 RECENT DEVELOPMENTS 509
19.6 ANGLE PLC (2022) 510
19.6.1 COMPANY SNAPSHOT 510
19.6.2 REVENUE ANALYSIS 510
19.6.3 PRODUCT PORTFOLIO 511
19.6.4 RECENT DEVELOPMENT 511
19.7 BIOCEPT, INC. 512
19.7.1 COMPANY SNAPSHOT 512
19.7.2 REVENUE ANALYSIS 512
19.7.3 PRODUCT PORTFOLIO 513
19.7.4 RECENT DEVELOPMENT 513
19.8 BIO-RAD LABORATORIES, INC. (2022) 514
19.8.1 COMPANY SNAPSHOT 514
19.8.2 REVENUE ANALYSIS 514
19.8.3 PRODUCT PORTFOLIO 515
19.8.4 RECENT DEVELOPMENTS 515
19.9 EPIC SCIENCES 516
19.9.1 COMPANY SNAPSHOT 516
19.9.2 PRODUCT PORTFOLIO 516
19.9.3 RECENT DEVELOPMENTS 516
19.10 FLUXION BIOSCIENCES INC 517
19.10.1 COMPANY SNAPSHOT 517
19.10.2 PRODUCT PORTFOLIO 517
19.10.3 RECENT DEVELOPMENTS 517
19.11 ILLUMINA, INC. 518
19.11.1 COMPANY SNAPSHOT 518
19.11.2 REVENUE ANALYSIS 518
19.11.3 SWOT ANALYSIS 519
19.11.4 PRODUCT PORTFOLIO 519
19.11.5 RECENT DEVELOPMENT 519
19.12 JOHNSON & JOHNSON PRIVATE LIMITED 521
19.12.1 COMPANY SNAPSHOT 521
19.12.2 REVENUE ANALYSIS 521
19.12.3 SWOT ANALYSIS 522
19.12.4 PRODUCT PORTFOLIO 522
19.12.5 RECENT DEVELOPMENTS 522

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.